Jefferies Reiterates Buy Rating on Olema Pharmaceuticals (OLMA)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
Go back to Jefferies Reiterates Buy Rating on Olema Pharmaceuticals (OLMA)
October 24, 2024 7:43 AM EDT
H.C. Wainwright analyst Emily Bodnar reiterated a Buy rating and $30.00 price target on Olema Pharmaceuticals (NASDAQ: OLMA).
The analyst commented: "This morning, Olema presented three preclinical data posters at EORTC-NCI-AACR Symposium including combinations of OP-3136 with fulvestrant or palazestrant and/or CDK4/6 inhibitors, and combinations of palazestrant with everolimus (mTOR inhibitor) or capivasertib (pan-AKT inhibitor). As a reminder, OP-3136 is the company's KAT6 inhibitor, which is an emerging target for the treatment... More
October 24, 2024 6:16 AM EDT
Goldman Sachs analyst Richard Law reiterated a Buy rating and $27.00 price target on Olema Pharmaceuticals (NASDAQ: OLMA).
The analyst comments "At the EORTC-NCi-AACR Symposium, OLMA presented preclinical in vitro and in vivo results for its KAT6 inhibitor OP-3136 vs. PFE's PF-07248144 as monotherapy, or in various doublet/triplet combinations with endocrine therapy (fulvestrant or pala) and/or CDK4/6i (ribociclib). For the... More
